Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,485
  • Shares Outstanding, K 510
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,830 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -10.26
  • Growth Rate Est. (year over year) +9,836.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.42 +20.25%
on 10/11/24
3.88 -25.00%
on 10/16/24
-0.75 (-20.49%)
since 09/18/24
3-Month
2.40 +21.25%
on 08/08/24
4.99 -41.68%
on 07/23/24
-1.46 (-33.39%)
since 07/18/24
52-Week
2.40 +21.25%
on 08/08/24
18.81 -84.53%
on 12/06/23
-9.87 (-77.23%)
since 10/18/23

Most Recent Stories

More News
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...

PHIO : 2.91 (+9.81%)
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp....

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference

Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology...

PHIO : 2.91 (+9.81%)
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

--Data will be presented at the conference in October in MontrealMarlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:...

PHIO : 2.91 (+9.81%)
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company...

PHIO : 2.91 (+9.81%)

Business Summary

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation,...

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.17
1st Resistance Point 3.04
Last Price 2.91
1st Support Level 2.74
2nd Support Level 2.57
3rd Support Level 2.44

See More

52-Week High 18.81
Fibonacci 61.8% 12.54
Fibonacci 50% 10.60
Fibonacci 38.2% 8.67
Last Price 2.91
52-Week Low 2.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar